Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Solid Tumor Testing Market Size Forecast: How Large Could The Market Become By 2030?

In the realm of solid tumor diagnostics, a robust expansion has been observed lately, with the market projected to surge from $29.94 billion in 2025 to $32.11 billion by 2026, reflecting a compound annual growth rate of 7.3%. This previous period of growth was propelled by significant developments in cancer detection methodologies, the identification of novel biomarkers, the increased automation within pathology workflows, a heightened general awareness surrounding oncology, and the implementation of various screening programs.

The market for solid tumor testing is poised for significant expansion over the coming years, projected to reach $43.19 billion by 2030, reflecting a compound annual growth rate of 7.7%. This anticipated surge is fueled by escalating demand for individualized treatment strategies, a heightened emphasis on early disease diagnosis, the broadening application of genomic analyses, the integration of artificial intelligence in diagnostic processes, and a general increase in oncology-focused research initiatives. Key developments expected to shape this market during the forecast period encompass a rise in liquid biopsy utilization, greater adoption of next-generation sequencing technologies, expanded implementation of companion diagnostics, the incorporation of AI in pathological assessments, and a greater prevalence of cancer screening programs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

Solid Tumor Testing Market Opportunity Drivers: What Is Creating New Revenue Potential?

The expanding occurrence of cancer is anticipated to be the primary catalyst for the advancement of the solid tumor testing sector in the future. Cancer, characterized by uncontrolled proliferation and dissemination of the body’s abnormal cells, refers to these rogue cells. These aberrant cells, designated as cancer cells, possess the capacity to infiltrate adjacent tissues and organs, and in certain scenarios, to metastasize to distant bodily locations via the circulatory or lymphatic pathways. Constituting approximately 90% of adult cancers, solid tumors represent the predominant form. Solid tumor testing serves the crucial purpose of identifying malignant cells within the bloodstream of individuals afflicted with solid tumors, even at stages where the malignancy remains undetectable through conventional imaging techniques. As an illustration, in July 2024, data sourced from the Australian Institute of Health and Welfare, a governmental entity based in Australia, indicated that in 2023, an estimated 165,000 individuals in Australia received a new cancer diagnosis. This figure translates to a daily incidence exceeding 450 cases, with males accounting for approximately 55% of these newly identified cancers. Consequently, the escalating incidence of cancer is demonstrably fueling the expansion of the solid tumor testing market.

Solid Tumor Testing Market Segment Analysis: What Are The Major Market Categories?

The solid tumor testing market covered in this report is segmented –

1) By Type: Genetic Testing, Conventional Testing

2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

3) By Application: Clinical, Research

4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

Subsegments:

1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

Solid Tumor Testing Market Innovation Trends Driving Future Development

Within the solid tumor testing sector, leading enterprises are concentrating their efforts on advancing novel solutions, specifically liquid biopsy platforms tailored for solid tumor analysis. These platforms involve a range of technologies and methodologies employed to scrutinize bodily fluids, predominantly blood, in pursuit of cancer-associated biomarkers. A case in point is PrognomiQ, a United States-based healthcare firm, which introduced its multi-omics liquid biopsy platform in January of 2023. Following this launch, PrognomiQ has commenced the subsequent phase of its product evolution by initiating a prospective clinical study involving 15,000 participants, with the initial patient having already been enrolled. The impetus behind this undertaking stems from the recognized capacity of multi-omics markers to effectively differentiate between cancerous conditions and non-cancerous controls.

Solid Tumor Testing Market Leading Companies Driving Competitive Growth

Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

Access The Complete Solid Tumor Testing Market Report:

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

Solid Tumor Testing Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the solid tumor testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model